Medical equipment company Sky Medical Technology receives King's Award for business innovation in recognition of the geko device
The Geko Device: A Revolutionary Advancement in Chronic Wound Care
The Geko device, a groundbreaking neuromuscular electrical stimulation (NMES) tool developed by Sky Medical Technology, is making waves in the field of chronic wound care. This innovative device, which employs the proprietary OnPulse technology, is designed to boost blood microcirculation, thereby accelerating recovery and enhancing chronic wound healing.
Clinical and Market Status
The Geko device has shown promising results in various clinical settings. For instance, a 2022 randomized feasibility trial on postoperative patients undergoing total hip replacement demonstrated trends of reduced pain, lower limb swelling, and shorter hospital stays, although the results were not statistically significant [1]. The device is also gaining recognition in wound care education and healthcare delivery, as evident in its adoption in places like Kitchener, Ontario for improving blood flow in wound healing [3].
The global wound care market, valued at over USD 23 billion in 2024, is expanding due to aging populations and rising chronic wound incidence [4]. The Geko device is part of this growing market, with its adoption rapidly escalating across multiple NHS primary care clinics.
Impact on Healthcare Delivery
The Geko device offers convenience and portability, allowing its use anytime and anywhere, thereby integrating preventive and therapeutic strategies beyond hospital settings. This could potentially reduce healthcare burdens by decreasing wound complications and enhancing recovery speed [2].
The Geko device's applications extend beyond wound care into muscle atrophy and other conditions requiring improved circulation or neuromuscular stimulation. Ongoing clinical trials are investigating broader indications such as cerebral palsy and rheumatoid arthritis [1].
Limitations and Considerations
While the Geko device shows promise, robust large-scale clinical evidence validating significant improvements over conventional therapy remains limited. Larger studies are needed to firmly establish its clinical effectiveness [1].
Although other NMES devices exist, the Geko’s unique OnPulse technology is noted for its specific impact on microcirculation. However, evidence distinguishing its superiority conclusively is still emerging [1][2].
Achievements and Recognition
The Geko device has been clinically proven to more than double the rate of wound healing [5]. The pivotal randomized self-controlled trial (RCT) for the Geko device has shown a more than twofold increase in the rate of chronic wound healing [5].
The Geko device's rapid effect on healing is being observed with its use, and clinicians are reporting immediate reductions in pain with its application [5]. The number of prescriptions for the Geko device is increasing by over 60% quarter-over-quarter for the last 3 consecutive quarters [6].
Q1 sales results for the Geko device are over budget, and the device is driving a transformation in chronic wound care, enabling scalable, cost-effective healthcare delivery across major markets [7].
The Geko device addresses the unmet need in chronic wound care with a clinically validated, non-invasive therapy that is now demonstrating a rapid rate of adoption from its UK commercial launch in February 2024 [7].
Sky Medical Technology Ltd, the innovator and manufacturer of the Geko device, has been awarded the King's Award for Enterprise in Innovation for its breakthrough wound care technology [8]. Fiona Young, Firstkind Wound Therapy Business Director, commented that the Geko device delivers real-world value clinically, operationally, and economically [8].
Chronic wounds remain a critical global health challenge, costing healthcare systems billions annually, according to the company [7]. The Geko device, with its rapid rate of adoption and promising clinical results, is poised to make a significant impact in addressing this challenge.
- In the field of health-and-wellness, the Geko device, a revolutionary advancement in chronic wound care, leverages medical-conditions-focused technology to accelerate recovery and enhance chronic wound healing, contributing to the growing global medical plastics market.
- The science-backed Geko device, employed in various clinical settings and healthcare delivery, addresses an unmet need in chronic wound care, offering benefits beyond hospital settings such as reducing healthcare burdens by decreasing wound complications and enhancing recovery speed.
- The Geko device, recognized for its clinical achievements, has shown promise in wound care but requires robust large-scale clinical evidence to conclusively establish its superiority over conventional therapy, with ongoing research exploring broader applications like cerebral palsy and rheumatoid arthritis.
